⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 3, 2024Expert Opinion on Drug Safety

Post-marketing safety concerns with elagolix: a disproportionality analysis of the FDA adverse event reporting system

En Chang Yongfang Shi Jinfeng Liu Wei Wei

View at Publisher

Ask AI

Bookmark

Share

Abstract

Objective Elagolix is approved for the treatment of moderate-to-severe pain associated with endometriosis. However, the long-term safety of elagolix in a large sample of real-world patients is unknown.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chang et al. (2024) studied this question.

synapsesocial.com/papers/68e6ba7eb6db64358763bc04 https://doi.org/10.1080/14740338.2024.2351451

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH AntagonistBlinded Clinical Trial · 2017 · 506 citations
2Efficacy of Elagolix and Relugolix for the Treatment of Pelvic Pain in Patients With Endometriosis: A Systematic Review2025 · 2 citations
3Efficacy and Safety of Elagolix Versus Dienogest for Treatment of Moderate‐to‐Severe Endometriosis Pain: A Phase <scp>III</scp> , Multicentric, Double‐Blind, Active‐Controlled, Non‐Inferiority StudyHuman Clinical Trial · 2026
4Elagolix Beyond the Ovary: A Novel Approach to Endometriosis ManagementObservational Study · 2026
5Comparative post-marketing reporting signals of elagolix and myfembree in endometriosis: a FAERS pharmacovigilance studyOriginal Research · 2026

More related papers

Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 trial2024
Single‐Dose Bioequivalence Study of Elagolix Tablets 200 mg (Test Product) and Elagolix Tablets 200 mg (Reference Product) in Healthy Non‐Pregnant, Non‐Lactating Premenopausal Female Subjects Under Fasting Conditions2026
Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids2020

More from Expert Opinion on Drug Safety

Long-term safety of treatment of hemophilia A: a comprehensive reviewTue,
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCTWed,